Docket No.

202617US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Man S. CO, et al.

SERIAL NO: 09/763,129

GAU:

1644

FILED:

May 16, 2001

EXAMINER: Gambel, P.

ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL

ANTIBODY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

MISSIONER FOR PATENTS TRADENEEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Tel. (703) 413-3000

Customer Number

Fax. (703) 413-2220 (OSMMN 05/03)

Vincent K. Shier, Ph.D. Registration No. 50,552

04/06/2004 JBALINAN 00000118 09763129

02 FC:1806

180.00 OP

PR 0 5 2004	U.S. DEPARTMENT PATENT AND TRAD	EMARK OFFICE	ATTY DOCKET NO. 202617US0PCT APPLICANT	- <u></u> -	SERIAL 1 09/763,			
LISTOF REFERE					09/763,	129		
PR 0 5 2004	NCES CITED BY API		ADDITIONT		09/763,129			
PR 0 5 2004	NCES CITED BY API							
PR 0 5 2004		PLICANT	Man S. CO, et al.	 -	,			
PR 0 5 2004 بير			FILING DATE		GROUP			
ايم APR 0 5 2004			May 16, 2001	1644				
. E			U.S. PATENT DOCUMENTS					
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS		NG DATE PROPRIATE	
AA								
AB		, 						
AC								
AD								
AE								
AF								
AG								
AH								
Al							<u>. </u>	
AJ								
AK								
AL								
AM		ļ						
AN								
	1.0	FC	REIGN PATENT DOCUMENTS		,			
	DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO			
AO								
AP								
AQ								
AR								
AS								
AT								
AU					<u></u>			
AV								
	OTHER R	EFERENCES	(Including Author, Title, Date, Pertir	nent Pages, e	etc.)			
AW A	A. MANHEIMER-LOR ASSOCIATED IDIOT	Y, et al., "MOI (PE", J. Exp. I	ECULAR CHARACTERISTICS OF A Med., Vol. 174, December 1991, pp. 10	NTIBODIES E 639-1652	BEARING A	AN ANTI-E	DNA-	
AX								
AY								
AZ				☐ Ado	Additional References sheet(s) attached			
Examiner				Date Co	Date Considered			
			ot citation is in conformance with MPE					

Docket No.

202617US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Man S. CO, et al.

SERIAL NO:

09/763,129

GAU:

FILED:

May 16, 2002

EXAMINER:

FOR:

ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL

ANTIBODY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MATER & NEUSTADT, P.C.

Norman F. Oblo

Registration No. 24

Surinder Sachar

Registration No. 34,423

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 03/02)

Form PTO 1449		U.S. DEPARTMENT OF COMMERCE		ATTY DOCKET NO.		SERIAL NO.		
(Modified) PATENT AND TRADEMARK OFFICE			202617US0PCT	09/763,129				
				APPLICANT				
LIST OF	REFE	RENCES CITED BY APP	LICANT	Man S. CO, et al.				
				FILING DATE		GROUP		
				May 16, 2002				
				U.S. PATENT DOCUMENTS				
EXAMINER		DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE	
INITIAL		NUMBER			05.00	CLASS	IF APPROPRIATE	
	AA							
	AB							
	AC	1.			<u>.</u>			
	AD				<u> </u>			
	AE	·						
·	AF				$\perp C$	ρ		
	AG					(C)		
	AH				PI.			
	ΑI					4		
	AJ					,	U	
	AK							
	AL							
	AM					·		
	AN				<u> </u>			
7			FO	REIGN PATENT DOCUMENTS				
							:	
				COUNTRY		TRANSLATION		
		DOCUMENT NUMBER	DATE	COUNTRY				
	AO		DATE	COUNTRY		YES		
	AO AP		DATE	COUNTRY				
	AP		DATE	COUNTRY				
	AP AQ		DATE	COUNTRY				
	AP AQ AR		DATE	COUNTRY				
	AP AQ AR AS		DATE	COUNTRY				
	AP AQ AR AS AT		DATE	COUNTRY				
	AP AQ AR AS AT AU		DATE	COUNTRY				
	AP AQ AR AS AT	NUMBER				YES		
	AP AQ AR AS AT AU	NUMBER OTHER REF	ERENCES (I	ncluding Author, Title, Date, Pertiner	• •	YES	S NO	
	AP AQ AR AS AT AU AV	OTHER REF	ERENCES (I		• •	YES	S NO	
	AP AQ AR AS AT AU	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplen	ERENCES (I	ncluding Author, Title, Date, Pertiner	• •	YES	S NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplen	ERENCES (I i-von willebra nental 10, pa	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplem 1996 KAGEYAMA et al.: "Antiwillebrand factor"	ERENCES (I i-von willebra nental 10, pa -thrombotic e	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a m	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Ant hamster" BLOOD, vol. 88, supplen 1996 KAGEYAMA et al.: "Anti willebrand factor" BRITISH JOURNAL OF	ERENCES (I i-von willebra nental 10, pa -thrombotic e	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplen 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Preven	ERENCES (I i-von willebra nental 10, pa -thrombotic e	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a m	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Prevent anticoagulant activity"	ERENCES (I i-von willebra nental 10, pa -thrombotic c PHARMACO	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a mLOGY, vol. 122, pages 165-171 all thrombosis using a novel heparin with	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Prevent anticoagulant activity"	ERENCES (I i-von willebra nental 10, pa -thrombotic c PHARMACO	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a m	inhibits arte	tc.)	s NO	
	AP AQ AR AS AT AU AV	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Prevent anticoagulant activity" JOURNAL OF VASCULA	ERENCES (I i-von willebra nental 10, pa -thrombotic c PHARMACO	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a mLOGY, vol. 122, pages 165-171 all thrombosis using a novel heparin with	nonoclonal a	tc.) antibody a	s NO It venous thrombosis in the gainst human von	
	AP AQ AR AS AT AU AV AW	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Prevent anticoagulant activity" JOURNAL OF VASCULA	ERENCES (I i-von willebra nental 10, pa -thrombotic c PHARMACO	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a mLOGY, vol. 122, pages 165-171 all thrombosis using a novel heparin with	nonoclonal a	tc.) antibody a	s NO	
Examiner	AP AQ AR AS AT AU AV AW	OTHER REF YAMAMOTO et al.: "Anthamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Antiwillebrand factor" BRITISH JOURNAL OF 1997 POLETTI et al.: "Prevent anticoagulant activity" JOURNAL OF VASCULA	ERENCES (I i-von willebra nental 10, pa -thrombotic c PHARMACO	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a mLOGY, vol. 122, pages 165-171 all thrombosis using a novel heparin with	nonoclonal a	tc.) antibody acantiplatele	s NO It venous thrombosis in the gainst human von	
*Examiner: Ini	AP AQ AR AS AT AU AV AW AX AY	OTHER REFI YAMAMOTO et al.: "Anti- hamster" BLOOD, vol. 88, supplent 1996 KAGEYAMA et al.: "Anti- willebrand factor" BRITISH JOURNAL OF 1 1997 POLETTI et al.: "Prevent anticoagulant activity" JOURNAL OF VASCULA 1997	ERENCES (I i-von willebra nental 10, pa -thrombotic e PHARMACO tion of arteria AR SURGER	ncluding Author, Title, Date, Pertiner and factor antibody AJvW-2 specifically rt 1-2, page 677, Abstract 172A effects and bleeding risk of AJvW-2, a mLOGY, vol. 122, pages 165-171 all thrombosis using a novel heparin with	nonoclonal and enhanced Addi Date Cor	tc.) erial but no antibody a antiplatele	s NO It venous thrombosis in the gainst human von et activity and reduced erences sheet(s) attached	